MOTS-c vs Tesofensine

MOTS-c and Tesofensine occupy different positions in the research landscape. MOTS-c is a mitochondrial peptide that signals energy stress and metabolic adaptation, while Tesofensine is a centrally acting small molecule that modulates monoamine tone. The former is studied for its roles in glucose handling, exercise adaptation, and age-related decline; the latter for appetite-related pathways and energy expenditure. The evidence base is asymmetric: MOTS-c findings come largely from rodent models and one Phase 1 study of a modified analog, whereas Tesofensine has completed Phase 2 trials with measurable physiological effects in humans. That disparity is central to any comparison. For researchers, the choice is not between two similar metabolic peptides but between a mitochondrial signaling peptide with broad preclinical promise and a clinically studied monoamine reuptake inhibitor with a distinct side-effect profile.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S rRNA gene (MT-RNR1). Discovered in 2015 by Lee et al. at USC, it acts as a metabolic regulator primarily through AMPK activation. In mouse models, MOTS-c prevents diet-induced obesity and insulin resistance, enhances exercise capacity (old mice ran 2x longer on treadmill tests), and reduces age-related metabolic decline. A modified analog (CB4211) showed good tolerability in a Phase 1 human trial. No clinical trials of native MOTS-c in humans have been completed.

Key claims: Improves insulin sensitivity and glucose metabolism; Exercise mimetic effects; Anti-obesity effects.

Tesofensine is a triple monoamine reuptake inhibitor targeting serotonin, norepinephrine, and dopamine transporters. It was originally developed for Alzheimer's and Parkinson's disease, and its development track later shifted toward metabolic research. In Phase 2 trials, it produced approximately 10% reduction in body weight over 24 weeks, an effect size that positioned it among the more potent body-weight agents studied in clinical settings. It is not technically a peptide by structure but is frequently included in peptide-focused discussions because it competes in the same metabolic research niche. The compound was originally developed by NeuroSearch A/S and later licensed to Saniona, which pursued Phase 3 trials. Its mechanism is distinct from mitochondrial and incretin-based approaches, with action concentrated on central monoamine signaling. The Tesofensine evidence base is more clinically mature than MOTS-c, but this maturity also brings a more defined adverse-event profile.

The apparent overlap between these compounds is narrower than it first appears. MOTS-c research clusters around metabolic health and aging biology — insulin sensitivity, glucose metabolism, mitochondrial function, and exercise tolerance. Tesofensine research centers on appetite suppression and energy balance, with most studies measuring food intake and body weight. The two intersect at metabolic regulation but diverge in mechanism and experimental endpoints. Researchers studying mitochondrial stress or age-related metabolic decline would not find a clear rationale for Tesofensine; investigators examining monoaminergic control of feeding would not substitute MOTS-c. The shared 'metabolism' label obscures the fact that these compounds address different research questions and operate through non-overlapping pathways.

Safety profiles are unequally characterized. MOTS-c has no reported adverse effects in preclinical animal studies, yet human data for the native peptide are absent. The only clinical exposure came from CB4211, a modified analog, which was well tolerated in Phase 1. That leaves native MOTS-c with a favorable but unverified human tolerability profile. Tesofensine has more human safety data from Phase 2, including a dose-dependent increase in resting heart rate of roughly 5–8 beats per minute and elevated blood pressure at higher doses. Common adverse effects included dry mouth, insomnia, constipation, nausea, and diarrhea. Consistent with its monoaminergic activity, psychiatric effects such as anxiety and mood changes were also reported. The contrast is not simply safety versus risk; rather, Tesofensine offers known clinical risks, while MOTS-c's risks are largely unknown.